Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1Classical hematology 1

Conditions

Venous Thromboembolism 1Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Hemorrhage 1Carcinoma, Non-Small-Cell Lung 1

Interventions

ruxolitinib 8fludarabine phosphate 3bomedemstat 3Whole-Body Irradiation 3Tacrolimus 3Specimen Handling 3Mycophenolic Acid 3Cyclophosphamide 3Biopsy 3fludarabine 2Stem Cell Transplantation 2Peripheral Blood Stem Cell Transplantation 2Methotrexate 2Melphalan 2Injections 2Busulfan 2venetoclax 1veliparib 1piperine 1pevonedistat 1iadademstat 1fedratinib 1demethoxycurcumin 1decitabine and cedazuridine drug combination 1anagrelide 1X-Rays 1Valganciclovir 1Transplantation 1Topotecan 1Therapeutics 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thrombocythemia, Essential × N(4)-oleylcytosine arabinoside × 1 year × Clear all
NCT05198960 2026-03-20

AVAJAK

University Hospital, Brest

Phase 3 Recruiting
1,308 enrolled
Classical hematologyMyeloid

Hemorrhage, Polycythemia Vera, Thrombocythemia, Essential, Venous Thromboembolism, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡